Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;5(5):273-81.
doi: 10.1038/nrrheum.2009.53.

Lupus mesenteric vasculitis can cause acute abdominal pain in patients with SLE

Affiliations
Review

Lupus mesenteric vasculitis can cause acute abdominal pain in patients with SLE

Ji Hyeon Ju et al. Nat Rev Rheumatol. 2009 May.

Abstract

Lupus mesenteric vasculitis (LMV) is a unique clinical entity found in patients who present with gastrointestinal manifestations of systemic lupus erythematosus, and is the main cause of acute abdominal pain in these patients. LMV usually presents as acute abdominal pain with sudden onset, severe intensity and diffuse localization. Other causes of abdominal pain, such as acute gastroenteritis, peptic ulcers, acute pancreatitis, peritonitis, and other reasons for abdominal surgery should be ruled out. Prompt and accurate diagnosis of LMV is critical to ensure implementation of appropriate immunosuppressive therapy and avoidance of unnecessary surgical intervention. The pathology of LMV comprises immune-complex deposition and complement activation, with subsequent submucosal edema, leukocytoclastic vasculitis and thrombus formation; most of these changes are confined to small mesenteric vessels. Abdominal CT is the most useful tool for diagnosing LMV, which is characterized by the presence of target signs, comb signs, and other associated findings. The presence of autoantibodies against phospholipids and endothelial cells might provide information about the likelihood of recurrence of LMV. Immediate, high-dose, intravenous steroid therapy can lead to a favorable outcome and prevent serious complications such as bowel ischemia, necrosis and perforation.

PubMed Disclaimer

References

    1. Br Med J. 1959 Feb 28;1(5121):540-2 - PubMed
    1. Radiol Clin North Am. 1964 Apr;2:71-87 - PubMed
    1. Clin Exp Immunol. 1991 Aug;85(2):254-61 - PubMed
    1. Acta Radiol. 1997 Jan;38(1):115-20 - PubMed
    1. Lupus. 2003;12(8):612-6 - PubMed

Publication types

MeSH terms